Evidence map›Paper›PMID 42482023›Full record

ArticleWorld journal of surgical oncology2026

Clinical association between myelodysplastic syndrome and de novo bone metastasis in urothelial carcinoma.

Zhilong Zestel Shen, Gan Xu, Hao Zhang, Pengru Wang, Xin Zhang, Bo Li, Jianru Xiao, Wei Xu

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhilong Zestel Shen *Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Gan XuDepartment of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Hao Zhang *Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Pengru WangDepartment of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Xin Zhang *Department of Anesthesiology and Perioperative medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.
Bo Li *Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, #415 Fengyang Road, Shanghai, 200003, China. liboczspine@smmu.edu.cn.
Jianru XiaoDepartment of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Wei Xu *Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, #415 Fengyang Road, Shanghai, 200003, China. xuwei_spine@163.com.ORCID https://orcid.org/0000-0002-9931-8371

Funding

National Natural Science Foundation of China 32470786Science and Technology Innovation Plan Of Shanghai Science and Technology Commission 23Y11903600Shanghai Shuguang Program 22SG36
6 · The paper itself

Abstract

aimTo assess the association between myelodysplastic syndrome and de novo bone metastasis of urothelial carcinoma.

methodA cohort of 145,719 patients with MDS and/or UTCA included from the surveillance, epidemiology, and end results (SEER) database was conducted to assess the risk of de novo bone metastasis of UTCA (DNBM-UTCA) in patients with previously diagnosed myelodysplastic syndrome (PD-MDS). The odds ratio for developing DNBM-UTCA between MDS and non-MDS patients was estimated. Weibull accelerated failure time model was applied to evaluate the survival outcomes of patients with UTCA.

resultsOur findings suggest that PD-MDS is a powerful risk factor for DNBM-UTCA (adjusted odds ratio, 6.428; 95% CI, 1.866-16.497; p < 0.001) and a poor prognostic factor on survival (adjusted survival time ratio, 0.485; CI, 0.338-0.695; p < 0.001).

conclusionOur findings suggest that PD-MDS was associated with higher odds of DNBM-UTCA and poorer survival outcomes, which may warrant additional clinical attention during treatment decision-making. However, these findings should be considered hypothesis-generating rather than causal. Further prospective studies and mechanistic investigations are needed to better clarify the biological basis underlying the observed association between PD-MDS and bone metastasis in UTCA.

Indexed as

Bone NeoplasmsCarcinoma, Transitional CellMyelodysplastic SyndromesUrologic NeoplasmsAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRisk FactorsSEER ProgramSurvival RateBone metastasisMyelodysplastic syndromePre-metastatic nicheUrothelial carcinoma

Identifiers

PMID42482023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.